Why Figs Stock Keeps Going Up
Figs (NYSE: FIGS) shares rose for a fourth straight day, up about 3.5% by 9:45 a.m. ET. After reporting Q2 results, the company said sales rose 29% to $196.6 million and GAAP net profit increased 300% YoY. Analysts cited by the article set price targets between $16 (Telsey) and $20 (Barclays, KeyBanc).
How this was made
The 30-second read
Why it matters
Earnings beat and strong growth metrics (sales +29% YoY, scrubs +26%, non-scrubs +40%, international +67%) plus GAAP net profit +300% and FCF turning positive are the core drivers. Analyst divergence (Telsey cut to $16 vs Barclays and KeyBanc raised to $20) suggests a contested valuation outlook.
Market read
Traders can use the earnings beat metrics and the specific target changes to gauge whether momentum is likely to persist versus valuation-driven mean reversion.
What to watch
It does not provide guidance, margin trajectory details, or inventory/returns risk; without those, the durability of the earnings-driven rerating is uncertain.
Background
The piece frames FIGS’ recent run-up as a continuation of post-earnings momentum, citing Q2 growth and analyst target changes.
Ticker impact
FIGS shares rose for four straight days and the article cites earnings where profit beat forecasts and sales grew 29% YoY.
Near-term upside bias while the market digests the earnings beat and raised targets; pullbacks possible if valuation narrative dominates.
The text provides concrete earnings outperformance (profit 2x forecast, GAAP net profit +300%, FCF turned positive) plus two specific analyst target increases to $20, which can extend momentum beyond the initial print.
Market effects
Supports the narrative that branded medical apparel demand is accelerating, potentially lifting sentiment for scrubs and healthcare retail supply chains.
No specific regional impact described.
No explicit global macro or international policy linkage beyond FIGS’ reported international sales growth.
Counterpoint
The article flags a lofty 38x P/E and notes one analyst cut the price target to $16, implying upside may be priced in and further gains could be limited by valuation.
Key entities
- public_companyFIGS
Scrubs supplier whose Q2 earnings beat and subsequent analyst target changes are cited as reasons for the stock’s multi-day rise.
- analyst_firmTelsey Advisory
Lowered its FIGS price target to $16 after the earnings report.
- analyst_firmBarclays
Raised its FIGS price target to $20, cited as bullish by the article.
- analyst_firmKeyBanc
Raised its FIGS price target to $20, cited as bullish by the article.
